HEMGENIX
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.1M | 854 | 169 |
| 2023 | $698,972 | 788 | 190 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $899,800 | 347 | 50.6% |
| Unspecified | $434,814 | 119 | 24.5% |
| Consulting Fee | $221,850 | 56 | 12.5% |
| Travel and Lodging | $170,538 | 470 | 9.6% |
| Food and Beverage | $30,350 | 612 | 1.7% |
| Royalty or License | $15,200 | 2 | 0.9% |
| Honoraria | $3,650 | 1 | 0.2% |
| Education | $1,884 | 35 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B | CSL Behring | $256,936 | 0 |
| An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B | CSL Behring | $151,584 | 0 |
| Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies | CSL Behring | $26,294 | 0 |
Top Doctors Receiving Payments for HEMGENIX — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Emily Thatcher | Student in an Organized Health Care Education/Training Program | Verplanck, NY | $248.65 | 6 |
| , NP | Family | New Orleans, LA | $248.17 | 2 |
| , A.P.R.N | Pediatrics | Hartford, CT | $240.09 | 2 |
| , FNP-BC | Family | Hartford, CT | $240.09 | 2 |
| , M.D | Hematology & Oncology | Worcester, MA | $233.27 | 2 |
| , MD | Hematology | Knoxville, TN | $233.27 | 2 |
| , CRNP | Nurse Practitioner | Long Beach, CA | $187.99 | 2 |
| , MD | Pediatric Hematology-Oncology | Indianapolis, IN | $178.89 | 3 |
| , ARNP | Registered Nurse | Miami, FL | $178.89 | 3 |
| , MD | Geriatric Medicine | Baton Rouge, LA | $178.89 | 3 |
| , MD | Hematology | Chapel Hill, NC | $178.89 | 3 |
| , MD, MBA | Pediatrics | Valhalla, NY | $170.24 | 3 |
| , MD | Pediatric Hematology-Oncology | Hawthorne, NY | $168.26 | 3 |
| , M.D | Pediatrics | Greer, SC | $159.61 | 2 |
| , PCNS | Pediatric Hematology-Oncology | Greenville, SC | $159.61 | 2 |
| , M.D | Pediatric Hematology-Oncology | Greenville, SC | $148.74 | 2 |
| , MS, RN, CPNP | Pediatrics | Hawthorne, NY | $144.65 | 6 |
| , CPNP | Pediatrics | Las Vegas, NV | $144.39 | 2 |
| , MD | Hematology | Honolulu, HI | $138.88 | 2 |
| , M.D | Medical Oncology | Honolulu, HI | $138.88 | 2 |
| , M.D | Hematology & Oncology | Saint George, UT | $132.51 | 2 |
| , DO | Pediatrics | Columbia, SC | $130.29 | 2 |
| , MD | Gastroenterology | Plantation, FL | $125.00 | 1 |
| , MD | Internal Medicine | Shreveport, LA | $125.00 | 1 |
| , CPNP | Pediatrics | Bossier City, LA | $125.00 | 1 |
Manufacturing Companies
- CSL Behring $1.8M
Product Information
- Type Biological
- Total Payments $1.8M
- Total Doctors 298
- Transactions 1,642
About HEMGENIX
HEMGENIX is a biological associated with $1.8M in payments to 298 healthcare providers, recorded across 1,642 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2023 to 2024. In 2024, $1.1M was paid across 854 transactions to 169 doctors.
The most common payment nature for HEMGENIX is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($899,800, 50.6% of total).
HEMGENIX is associated with 3 research studies, including "Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B" ($256,936).